合同纠纷案一审判赔，科源制药下调去年归母净利润预期

Core Viewpoint - Shandong Keyuan Pharmaceutical Co., Ltd. has significantly revised its 2025 profit forecast, expecting a net profit decline of 70%-80% due to an unexpected legal dispute involving its subsidiary [1][2] Group 1: Profit Forecast Revision - The company revised its expected net profit from a previous estimate of 27.20 million to 39.29 million yuan (a decline of 35%-55%) to a new range of 12.09 million to 18.13 million yuan (a decline of 70%-80%) [1][2] - The legal dispute involves a compensation of 16.11 million yuan that will be recognized as an extraordinary expense, impacting the net profit [1][2] Group 2: Legal and Financial Implications - The subsidiary, Shandong Linuo Pharmaceutical Co., Ltd., has had some bank accounts frozen due to the legal dispute, with 57 million yuan frozen, representing 4.19% of the company's latest audited net assets [2] - The ongoing legal issues have the potential to affect the normal operations of the subsidiary [2] Group 3: Historical Performance and Challenges - In 2023, the company reported a revenue of 448 million yuan, a slight increase of 1.07%, but net profit decreased by 15.60% to 77.04 million yuan [2] - For 2024, revenue grew by 3.60% to 464 million yuan, but net profit fell to 60.45 million yuan, a decline of 21.54% [2] - The first three quarters of 2025 showed continued deterioration, with revenue at 303 million yuan (down 8.5%) and net profit at 31.47 million yuan (down 20.7%) [2] Group 4: Strategic Moves and Acquisitions - The company attempted to find new growth through acquisitions, planning to acquire 99.42% of Hongjitang for up to 3.581 billion yuan, which was seen as a significant asset restructuring [3][4] - The acquisition was expected to enhance the company's business by integrating traditional Chinese medicine with chemical pharmaceuticals, aiming for cost reduction and improved operational efficiency [4] Group 5: Termination of Acquisition - On November 28, the company decided to terminate the acquisition due to changes in the overall market environment, which were not elaborated upon [5] - The acquisition price was deemed excessively high, equating to 7.7 times the company's 2024 revenue and 59 times its net profit, far exceeding its capital capacity [5]